Mobileye Q3 Revenue Slips 2% to $492M; Full-Year Outlook Raised to $1.995B-$2.02B
MBLY is trading near its 52-week low of $6.4 (1.6% above the low).
Summary
Mobileye reported Q3 revenue of $492 million, down 2%, with adjusted operating income of $89 million, and nudged its full-year revenue outlook up to $1.995-$2.02 billion. The beat on profit leans on a $52 million non-cash R&D incentive grant, while the balance sheet holds $1.5 billion in cash and investments.
Key Events · Earnings and Guidance · MBLY
-
Q3 Revenue Falls 2% to $492M
Revenue declined from $504 million a year ago as average system price dropped to $49.1 from $51.7 on a higher mix of lower-content China OEM exports; EyeQ volumes partially offset the decline.
-
Full-Year Revenue Outlook Raised
Guidance narrowed and lifted to $1,995-$2,020 million, a $13 million midpoint increase implying 5%-7% growth; adjusted operating income guidance midpoint rose about 1% to $380-$420 million.
-
Profit Boosted by R&D Grant
Q3 GAAP and non-GAAP operating income included $52 million and $51 million from an Israeli R&D Law incentive grant ($162 million and $144 million year-to-date); cash receipts are expected to begin around 2028.
-
Balance Sheet and Buyback
The company held $1.5 billion in cash, cash equivalents, marketable securities and deposits, generated $303 million of operating cash flow in the first nine months, and repurchased $33 million of stock under the April 23, 2026 program.
Analysis · MBLY · Technology
Revenue fell 2% to $492 million as a richer mix of lower-content China OEM exports cut average system price to $49.1 from $51.7 a year ago, but margins improved and the company raised the midpoint of its full-year revenue outlook by $13 million. The profit picture is flattered by a $52 million Israeli R&D Law incentive grant booked in Q3 ($162 million year-to-date) that will not be collected in cash until roughly 2028, so the underlying operating improvement is smaller than the headline adjusted numbers suggest. With the stock near its 52-week low of $6.40, the raised guidance and $1.5 billion liquidity cushion are the key supports; the risk is that a sustained low share price forces further goodwill testing on the $4.9 billion balance that remains after the $3.788 billion Q1 impairment.
How filings like this one have moved
In the 30 days to Nov 15, 2026, 37.5% of the 3713 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MBLY was trading at $6.50 on NASDAQ in the Technology sector, with a market capitalization of approximately $6B. The 52-week trading range was $6.40 to $14.33. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.